HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 3%, Taijili Ding injection clinical trials approved.
Hengrui Medicine (01276) rose nearly 3%, as of the time of publication, up 1.76% to 72.35 Hong Kong dollars, with a turnover of 3758.86 million Hong Kong dollars.
Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 3%, as of the time of writing, up 1.76% to HK$72.35, with a turnover of HK$37.5886 million.
On the news front, on November 17, Jiangsu Hengrui Pharmaceuticals announced that the company has received the Drug Clinical Trial Approval Notice for Fumaryl Oliceridine Injection from the National Medical Products Administration (NMPA), and will conduct clinical trials in the near future.
Fumaryl Oliceridine Injection is a -opioid receptor (MOR) biased small molecule agonist. It was approved for market in China in January 2024 as the first domestically researched and developed Class 1 opioid analgesic innovative drug. A similar product developed by Trevena, Oliceridine (trade name: Olinvyk), was approved for sale in the United States in 2020. Jiangsu Nhwa Pharmaceutical Co., Ltd. has obtained exclusive licensing rights for Oliceridine from Trevena. Oliceridine was approved for market in China in May 2023, but sales data is not yet available. Up to now, the total research and development investment in the Fumaryl Oliceridine Injection project is approximately 200 million RMB.
Related Articles
HK Stock Market Move | MAOYAN ENT (01896) drops over 2% again, stock price has fallen by 10% in the last three days. The box office of "Demon Slayer" has significantly decreased after 3 days of release.
Broadcom Inc. (AVGO.US) faces lawsuit from financial giant Fidelity after strong push for "bundled sales" following acquisition of VMware.
Caitong: Self-driving taxis are advancing globally, focusing on existing mature experiences and upcoming entry targets.
HK Stock Market Move | MAOYAN ENT (01896) drops over 2% again, stock price has fallen by 10% in the last three days. The box office of "Demon Slayer" has significantly decreased after 3 days of release.
Broadcom Inc. (AVGO.US) faces lawsuit from financial giant Fidelity after strong push for "bundled sales" following acquisition of VMware.
Caitong: Self-driving taxis are advancing globally, focusing on existing mature experiences and upcoming entry targets.
RECOMMEND
U.S. equities face “key defense lines,” testing bullish conviction; a break would confirm a downtrend into “early next year”
17/11/2025
Year-to-date Hong Kong share buybacks surpass HK$140 billion, with technology and financials leading activity
17/11/2025
Bitcoin’s year-to-date 30% rally “fully erased,” market slips into a bear phase
17/11/2025
